Table 3.
Basic clinical information of pure histological subtypes such as mean age, mean tumor and lymph node stage and available survival information. na: not available
| Subtype (n = 293) | Mean age (years) | Mean tumor size (mm) | Na | Mean involved axillary lymph nodes (n =) | Nodal positive (in percentage) | Na | Mean months overall survival | Lost of follow-up (n =) |
|---|---|---|---|---|---|---|---|---|
| Mucinous (n = 70) | 64.5 | 25.6 | 7 | 11 of 56 | 19.64% | 14 | 72.5 | 22 |
| Micropapillary (n = 62) | 61.4 | 24.3 | 4 | 34 of 52 | 65.38% | 10 | 77.8 | 11 |
| High-grade metaplastic (n = 38) | 60.2 | 32 | 7 | 12 of 29 | 41.38% | 9 | 50.8 | 8 |
| Male breast cancer (n = 24) | 65 | 20.5 | 3 | 10 of 19 | 52.63% | 5 | 65.5 | 5 |
| Cribriform (n = 20) | 54.7 | 15.4 | 3 | 2 of 17 | 11.76% | 3 | 60.5 | 5 |
| Metastases (n = 18) | 63.3 | 23 | 15 | 1 of 2 | 50.00% | 2 | 39.7 | 3 |
| Apocrine (n = 16) | 64.4 | 17.9 | 1 | 3 of 13 | 23.08% | 3 | 57.8 | 6 |
| Papillary (n = 16) | 70.7 | 28.4 | 1 | 2 of 12 | 16.67% | 4 | 52.4 | 3 |
| NST with clear cell features (n = 11) | 64.4 | 31 | 3 | 1 of 8 | 12.50% | 3 | 70.8 | 3 |
| NST with medullary features (n = 10) | 54.3 | 32.9 | 1 | 2 of 9 | 22.22% | 1 | 53.2 | 1 |
| High-grade neuroendocrine (n = 8) | 59.1 | 19.7 | 2 | 4 of 6 | 66.67% | 2 | 73.7 | 1 |